Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of cabozantinib in radioiodine-refractory differentiated thyroid cancer
2018-001771-21Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in well-differentiated thyroid cancer (WDTC) comparing Cabozantinib with Placebo (2 arms). Primary endpoints: Progression-free survival (PFS) and Objective response rate (ORR). Started Jan 2019; status: completed.
02
Drugs
cabozantinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2018-001771-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001771-21.